decernotinib decernotinib decernotinib is an inhibitor of janus kinase 3 (jak3) discovered through a process of inhouse screening of a chemical compound library. decernotinib also had the name vx-509 in development phase. it is an experimental drug with high selectivity for jak3, which demonstrates good efficacy in vivo in the rat host versus graft model (hvg). it is being studied in clinical trials at vertex. decernotinibidentifiers iupac name (2r)-2-methyl-2-pyridin-3-yl)pyrimidin-4-yl]amino]-n-(2,2,2-trifluoroethyl)butanamide cas number944842-54-0pubchem cid59422203chemspider30843790uniimzk2gp0rhkkeggd10585comptox dashboard (epa)dtxsid70241504 chemical and physical dataformulac18h19f3n6omolar mass392.386 g·mol−13d model (jsmol)interactive image smiles cc(c)(c(=o)ncc(f)(f)f)nc1=nc(=nc=c1)c2=cnc3=c2c=cc=n3 inchi inchi=1s/c18h19f3n6o/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9h,3,10h2,1-2h3,(h,22,24)(h,25,28)(h,23,26,27)/t17-/m1/s1key:asuguqwihmtfjl-qgzvfwflsa-n